Degenerate minigene library analysis enables identification of altered branch point utilization by mutant splicing factor 3B1 (SF3B1)

被引:5
|
作者
Gupta, Abhishek K. [1 ]
Murthy, Tushar [2 ]
Paul, Kiran, V [1 ]
Ramirez, Oscar [1 ]
Fisher, Joseph B. [3 ]
Rao, Sridhar [3 ]
Rosenberg, Alexander B. [4 ]
Seelig, Georg [5 ]
Minella, Alex C. [3 ]
Pillai, Manoj M. [1 ]
机构
[1] Yale Canc Ctr, Sect Hematol, New Haven, CT 06520 USA
[2] Northwestern Univ, Driskill Grad Program, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Bloodctr Wisconsin, Blood Res Inst, Milwaukee, WI 53233 USA
[4] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA
[5] Univ Washington, Paul G Allen Sch Comp Sci & Engn, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
MUTATIONS; MYELODYSPLASIA; SELECTION;
D O I
10.1093/nar/gky1161
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer-associated mutations of the core splicing factor 3 B1 (SF3B1) result in selection of novel 3splice sites (3SS), but precise molecular mechanisms of oncogenesis remain unclear. SF3B1 stabilizes the interaction between U2 snRNP and branch point (BP) on the pre-mRNA. It has hence been speculated that a change in BP selection is the basis for novel 3SS selection. Direct quantitative determination of BP utilization is however technically challenging. To define BP utilization by SF3B1-mutant spliceosomes, we used an overexpression approach in human cells as well as a complementary strategy using isogenic murine embryonic stem cells with monoallelic K700E mutations constructed via CRISPR/Cas9-based genome editing and a dual vector homology-directed repair methodology. A synthetic minigene library with degenerate regions in 3 intronic regions (3.4 million individual minigenes) was used to compare BP usage of SF3B1(K700E) and SF3B1(WT). Using this model, we show that SF3B1(K700E) spliceosomes utilize non-canonical sequence variants (at position -1 relative to BP adenosine) more frequently than wild-type spliceosomes. These predictions were confirmed using minigene splicing assays. Our results suggest a model of BP utilization by mutant SF3B1 wherein it is able to utilize non-consensus alternative BP sequences by stabilizing weaker U2-BP interactions.
引用
收藏
页码:970 / 980
页数:11
相关论文
共 50 条
  • [31] Influence of SF3B1 gene mutation is different from that of Sf3B1 inhibitor in colorectal cancer
    Yamano, Tomoki
    Kubo, Shuji
    Matsubara, Nagahide
    Yano, Aya
    Tomita, Naohiro
    CANCER RESEARCH, 2014, 74 (19)
  • [32] Mutant or overexpressed SF3B1 facilitates endometrial cancer tumorigenesis
    Popli, Pooja
    Deng, Xinchao
    Thaker, Premal
    Kommagani, Ramakrishna
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)
    Felicia Fei-Lei Chung
    Perry Faith Tze Ming Tan
    Vijay Joseph Raja
    Boon-Shing Tan
    Kuan-Hon Lim
    Toh-Seok Kam
    Ling-Wei Hii
    Si Hoey Tan
    Sze-Jia See
    Yuen-Fen Tan
    Li-Zhe Wong
    Wai Keat Yam
    Chun Wai Mai
    Tracey D. Bradshaw
    Chee-Onn Leong
    Scientific Reports, 7
  • [34] Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)
    Chung, Felicia Fei-Lei
    Tan, Perry Faith Tze Ming
    Raja, Vijay Joseph
    Tan, Boon-Shing
    Lim, Kuan-Hon
    Kam, Toh-Seok
    Hii, Ling-Wei
    Tan, Si Hoey
    See, Sze-Jia
    Tan, Yuen-Fen
    Wong, Li-Zhe
    Yam, Wai Keat
    Mai, Chun Wai
    Bradshaw, Tracey D.
    Leong, Chee-Onn
    SCIENTIFIC REPORTS, 2017, 7
  • [35] Targeting SF3B1 mediated splicing control in chronic lymphocytic leukemia
    Chen, Rong
    Plunkett, William
    Kipps, Thomas J.
    Wu, Catherine J.
    Keating, Michael
    Chen, Yuling
    Rassenti, Laura
    Gruber, Michaela
    Ghia, Emanuela
    Qi, Yuan
    Su, Xiaoping
    Wong, Jessica
    LEUKEMIA & LYMPHOMA, 2017, 58 : 219 - 219
  • [36] SF3B1 Splicing Mutation in the Context of Therapy-Related MDS
    Volpe, Virginia
    Al Ali, Najla
    Padron, Eric
    Sallman, David
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S320 - S320
  • [37] THE SPLICEOSOMAL COMPONENT SF3B1 IS ESSENTIAL FOR HEMATOPOIETIC DIFFERENTIATION AND SPLICING FIDELITY
    Bowman, Teresa
    Cameron, Rosannah
    McKinstry, Mia
    De La Garza, Adriana
    Nik, Sara
    Payne, Sara
    Smith, Peter
    Buonamici, Silvia
    Bradley, Robert
    EXPERIMENTAL HEMATOLOGY, 2016, 44 (09) : S51 - S51
  • [38] ABERRANT SPLICING DURING ERYTHROID DIFFERENTIATION IN SF3B1 MUTATED SIDEROBLASTIC
    Conte, S.
    Vesterlund, L.
    Katayama, S.
    Karimi, M.
    Unneberg, P.
    Papaemmanuil, E.
    Jansson, M.
    Mortera-Blanco, T.
    Dimitriou, M.
    Sander, B.
    Skoog, T.
    Campbells, P.
    Kere, J.
    Hellstrom-Lindberg, E.
    HAEMATOLOGICA, 2013, 98 : 73 - 74
  • [39] Understanding the Role of Mutations in SF3B1 and Splicing in Chronic Lymphocytic Leukemia
    Wu, Catherine J.
    BLOOD, 2012, 120 (21)
  • [40] GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies
    Benbarche, Salima
    Pineda, Jose Mario Bello
    Galvis, Laura Baquero
    Biswas, Jeetayu
    Liu, Bo
    Wang, Eric
    Zhang, Qian
    Hogg, Simon J.
    Lyttle, Kadeen
    Dahi, Ariana
    Lewis, Alexander M.
    Saechi, Martina
    Rahman, Jahan
    Fox, Nina
    Ai, Yuxi
    Mehta, Sanjoy
    Garippa, Ralph
    Ortiz-Pacheco, Juliana
    Li, Zhuoning
    Monetti, Mara
    Stanley, Robert F.
    Doulatov, Sergei
    Bradley, Robert K.
    Abdel-Wahab, Omar
    MOLECULAR CELL, 2024, 84 (10) : 1886 - 1903.e10